Alex Goldberg

Myriad Genetics Inc. (NASDAQ:MYGN) and Molex Incorporated (NASDAQ:MOLX) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 10/15/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Myriad Genetics Inc. (NASDAQ:MYGN) and Molex Incorporated (NASDAQ:MOLX).

Myriad Genetics Inc. (NASDAQ:MYGN) a molecular diagnostic company that focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States closed up in its previous session (+4.83%) on 3,101,992 shares traded after TheStreet Quant Ratings rated Myriad Genetics as a buy. Myriad Genetics Inc. (NASDAQ:MYGN) is currently up (+8.02%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Myriad Genetics Inc. (NASDAQ:MYGN)

Molex Incorporated (NASDAQ:MOLX) a company that together with its subsidiaries, engages in the design, manufacture, and sale of electronic components worldwide closed down in its previous session (-0.03%) on 1,451,654 shares traded. Molex Incorporated (NASDAQ:MOLX) is currently down (-1.11%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Molex Incorporated (NASDAQ:MOLX)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com